Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Hemorrhagic transformation (HT) following reperfusion therapies for acute
ischaemic stroke often predicts a poor prognosis. This systematic review and meta-analysis …

Objective: Patients experiencing acute ischemic stroke or transient ischemic attack are
commonly treated with clopidogrel and/or aspirin (mono-and dual-antiplatelet therapy) to …

The blood-brain barrier (BBB) hinders the distribution of therapeutics intended for treatment
of neuroinflammation (NI) of the central nervous system. A twelve-amino acid peptide that …

Objective Conflicting data exist on the safety and efficacy of IV thrombolysis (IVT) in patients
with acute ischemic stroke (AIS) receiving dual antiplatelet pretreatment (DAPP). The aim of …

Background and purpose To investigate the safety and efficacy of oral antiplatelet therapy
(APT) for patients who had acute ischaemic stroke (AIS), receiving endovascular therapy …

Background: The role of intravenous thrombolysis (IVT) as bridging treatment prior to
endovascular thrombectomy (EVT) is under debate and better patient selection is needed …

Background Intravenous thrombolysis (IVT) is a standard procedure for the treatment of
patients with acute ischemic stroke (AIS). Improving the therapeutic efficacy of IVT is an …

Aim To study the effects of pretreatment with Antiplatelet (AP) before IV thrombolysis (IVT) on
the rate of symptomatic intracranial hemorrhage (sICH) and functional outcome in patients …

Antithrombotic drugs (ADs) are the mainstay of secondary prevention of thrombotic vascular
diseases. Management of patients under long-term treatment with ADs admitted for acute …